ADAPTABLE, the Industry’s First Fully Decentralized Clinical Megatria

ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness) is the industry’s first fully decentralized clinical megatrial (DCT) and one of the largest DCTs to date. A pragmatic, patient-centered, randomized trial, the goal of the study was to determine the optimal aspirin dosage for Americans living with heart disease. 

Our webinar will cover:

• ADAPTABLE’s patient-centric design with an emphasis on extensive patient input, recruitment of diverse participants, and use of novel technologies reduced costs while ensuring reliable results, thus proving the many benefits that DCTs can provide to study sponsors, researchers and patients. 
• How the innovative project combined the expertise of academic and industry partners, nascent technology owned by Medidata and a patient-centered research network to prove DCTs can produce valuable information that aids doctors, patients and their caregivers in making real-world medical decisions.
  
• We will review how this study was the springboard to driving the adoption of DCTs and the development of new innovative technologies to increase patient safety, comprehensive data collection, and operational efficiencies.